CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleLevered free cash flow is $43.63M, above the global median of $16.24M
- PositionP/E ratio is 11.55×, lower than 95% of its Medical Devices peers (median 31.47×)
- Interpretations7 currently firing — 7
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
889.23MUSDvs all stocks (USD)
Trailing P/E
11.55xvs Medical Devices peers
Revenue (TTM)
374.64MUSDvs all stocks (USD)
Profit Margin
23.27%vs Medical Devices peers
Beta
1.91xvs all stocks
52-Week Change
10.82%vs all stocks
Market Capitalization
889.23MUSDvs all stocks (USD)
Enterprise Value
436.44MUSDvs all stocks (USD)
Trailing P/E
11.55xvs Medical Devices peers
Forward P/E
10.77xvs Medical Devices peers
PEG Ratio
-0.3754xvs Medical Devices peers
Price to Sales (TTM)
2.39xvs Medical Devices peers
Price to Book (MRQ)
1.45xvs Medical Devices peers
Enterprise to Revenue
1.17xvs Medical Devices peers
Enterprise to EBITDA
5.42xvs Medical Devices peers
Gross Margin
75.05%vs Medical Devices peers
Profit Margin
23.27%vs Medical Devices peers
Operating Margin
12.26%vs Medical Devices peers
Return on Assets (TTM)
6.86%vs Medical Devices peers
Return on Equity (TTM)
13.62%vs Medical Devices peers
Revenue (TTM)
374.64MUSDvs all stocks (USD)
Revenue per Share (TTM)
5.92USDUpdated Jul 19, 2026Quarterly Revenue Growth
5.30%vs Medical Devices peers
Gross Profit (TTM)
291.61MUSDvs all stocks (USD)
EBITDA (TTM)
80.52MUSDvs all stocks (USD)
Net Income (TTM)
87.19MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-36.50%vs Medical Devices peers
Operating Cash Flow (TTM)
86.60MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
43.63MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Medical Devices peers
Revenue
370.50MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
79.53MUSDFY2025 · Dec 31, 2025Gross Profit
290.97MUSDFY2025 · Dec 31, 2025Operating Income
85.39MUSDvs all stocks (USD)
Pre-tax Income
110.33MUSDFY2025 · Dec 31, 2025Income Tax Expense
16.50MUSDFY2025 · Dec 31, 2025Net Income
93.83MUSDFY2025 · Dec 31, 2025EBIT
85.39MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
86.08MUSDFY2025 · Dec 31, 2025Research & Development
13.32MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
192.26MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
24.94MUSDFY2025 · Dec 31, 2025EPS (Basic)
1.45USDFY2025 · Dec 31, 2025EPS (Diluted)
1.43USDFY2025 · Dec 31, 2025Basic Shares Outstanding
64.63MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
64.63MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
93.83MUSDFY2025 · Dec 31, 2025Operating Cash Flow
84.79MUSDFY2025 · Dec 31, 2025Free Cash Flow
83.82MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
302.54MUSDFY2025 · Dec 31, 2025Income Tax Paid
14.87MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
93.83MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
695.00KUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
2.93MUSDFY2025 · Dec 31, 2025Stock-based Compensation
11.13MUSDFY2025 · Dec 31, 2025Other Non-cash Items
498.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-11.13MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
4.13MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-17.29MUSDFY2025 · Dec 31, 2025Capital Expenditures
-972.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-313.51MUSDFY2025 · Dec 31, 2025Sale of Investments
500.52MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
186.03MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-127.44MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-127.44MUSDFY2025 · Dec 31, 2025Shares Outstanding
57.48MSharesUpdated Jul 19, 2026Float Shares
49.53MSharesUpdated Jul 19, 2026Shares Short
2.94MSharesUpdated Jul 19, 2026Short Ratio
3.75daysvs all stocks
Short % of Shares Outstanding
5.80%vs all stocks
% Held by Insiders
13.14%vs all stocks
% Held by Institutions
59.23%vs all stocks
Total Cash (MRQ)
537.16MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
8.47USDUpdated Jul 19, 2026Total Debt (MRQ)
4.83MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0073xvs Medical Devices peers
Current Ratio (MRQ)
8.80xvs Medical Devices peers
Book Value per Share (MRQ)
10.78USDUpdated Jul 19, 2026Total Assets
766.43MUSDvs all stocks (USD)
Total Current Assets
698.62MUSDFY2025 · Dec 31, 2025Total Liabilities
83.23MUSDFY2025 · Dec 31, 2025Total Non-current Assets
67.81MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
12.49MUSDFY2025 · Dec 31, 2025Total Current Liabilities
70.74MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
302.54MUSDFY2025 · Dec 31, 2025Other Short-term Investments
252.79MUSDFY2025 · Dec 31, 2025Accounts Receivable
43.50MUSDFY2025 · Dec 31, 2025Inventory
74.05MUSDFY2025 · Dec 31, 2025Accounts Payable
17.91MUSDFY2025 · Dec 31, 2025Short-term Debt
3.22MUSDFY2025 · Dec 31, 2025Deferred Revenue
12.09MUSDFY2025 · Dec 31, 2025Other Current Liabilities
15.96MUSDFY2025 · Dec 31, 2025Long-term Debt
5.01MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
4.44MUSDFY2025 · Dec 31, 2025Common Stock (Book)
251.00KUSDFY2025 · Dec 31, 2025Retained Earnings
968.53MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
683.20MUSDvs all stocks (USD)
Treasury Stock
495.27MUSDFY2025 · Dec 31, 202552-Week Low
12.72USDUpdated Jul 19, 202652-Week High
16.74USDUpdated Jul 19, 202652-Week Change
10.82%vs all stocks
Beta
1.91xvs all stocks
50-Day MA
14.06USDUpdated Jul 19, 2026200-Day MA
14.35USDUpdated Jul 19, 2026Avg 10-Day Volume
697.49KSharesUpdated Jul 19, 2026Avg 30-Day Volume
754.45KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
1.35USDUpdated Jul 19, 20267 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
Liquidity Ratios Elevated
It can cover near-term bills from cash alone, not just from inventory.
Reads
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
How does this company use capital?
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
How is this stock valued?
High Retained Earnings With Profitability And Equity
Profits kept in the business fund much of what it owns, after five straight profitable years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
P/E ratio is 11.55×, lower than 95% of its Medical Devices peers (median 31.47×)Notable
P/E ratio: 11.55Industry median: 31.47Industry P5: 13.95Peers compared: 102
Financial Health
Altman Z-Score 10.01: safe zoneNotable
Altman Z-Score: 10.01
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Levered free cash flow is $43.63M, above the global median of $16.24MNotable
Levered free cash flow (USD): 43,626,624Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Cloudbreak Pharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hpgc Renmintongtai Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
DNA Link Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Boji Medical & Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
LB Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Theravance Biopharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hubei Biocause Heilen Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sana Biotechnology, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shandong Wit Dyne Health Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
China Isotope & Radiation Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Nien Made Enterprise Co., Ltd.
7 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityCash-Flow Ratios ElevatedCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios ElevatedIndustry-Benchmarked ROA and Margin ElevatedLow-Leverage Liquidity Configuration
Jiangxi JDL Environmental Protection Co. Ltd.
6 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash-Flow Ratios ElevatedCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios ElevatedIndustry-Benchmarked ROA and Margin ElevatedLow-Leverage Liquidity Configuration
King Slide Works Co., Ltd.
7 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityCash-Flow Ratios ElevatedCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios ElevatedIndustry-Benchmarked ROA and Margin ElevatedLow-Leverage Liquidity Configuration